203 related articles for article (PubMed ID: 34812989)
1. Molecular subtyping of ependymoma and prognostic impact of Ki-67.
Lim KY; Lee K; Shim Y; Park JW; Kim H; Kang J; Won JK; Kim SK; Phi JH; Park CK; Chung CK; Yun H; Park SH
Brain Tumor Pathol; 2022 Jan; 39(1):1-13. PubMed ID: 34812989
[TBL] [Abstract][Full Text] [Related]
2. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
[TBL] [Abstract][Full Text] [Related]
3. Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications.
Chinnam D; Gupta K; Kiran T; Saraswati A; Salunke P; Madan R; Kumar N; Radotra BD
Brain Tumor Pathol; 2022 Jul; 39(3):151-161. PubMed ID: 35348910
[TBL] [Abstract][Full Text] [Related]
4. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.
Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Rajeshwari M; Singh M; Suri V; Sarkar C; Sharma MC
J Neurooncol; 2018 May; 138(1):29-39. PubMed ID: 29354850
[TBL] [Abstract][Full Text] [Related]
5. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?
Nambirajan A; Malgulwar PB; Sharma A; Boorgula MT; Doddamani R; Singh M; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2019 Oct; 36(4):152-161. PubMed ID: 31388782
[TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
[TBL] [Abstract][Full Text] [Related]
8. Survival and Prognostic Factors of Adult Intracranial Ependymoma: A Single-institutional Analysis of 236 Patients.
Zhao F; Wu T; Wang LM; Zhang J; Zhang H; Li SW; Zhang S; Li P; Wang B; Luo L; Liu PN
Am J Surg Pathol; 2021 Jul; 45(7):979-987. PubMed ID: 33739788
[TBL] [Abstract][Full Text] [Related]
9. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
12. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
[TBL] [Abstract][Full Text] [Related]
13. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters.
Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V
Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576
[TBL] [Abstract][Full Text] [Related]
14. Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.
Tauziède-Espariat A; Siegfried A; Nicaise Y; Kergrohen T; Sievers P; Vasiljevic A; Roux A; Dezamis E; Benevello C; Machet MC; Michalak S; Puiseux C; Llamas-Gutierrez F; Leblond P; Bourdeaut F; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Dangouloff-Ros V; Boddaert N; Saffroy R; Hasty L; Wahler E; Pagès M; Andreiuolo F; Lechapt E; Chrétien F; Blauwblomme T; Beccaria K; Pallud J; Puget S; Uro-Coste E; Varlet P;
Acta Neuropathol Commun; 2021 Aug; 9(1):135. PubMed ID: 34389065
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Benevides Silva FA; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Neurooncol; 2021 Oct; 155(1):13-23. PubMed ID: 34570300
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
17. Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.
de Sousa GR; Salomão KB; Nagano LFP; Riemondy KA; Chagas PS; Veronez LC; Saggioro FP; Marie SKN; Yunes JA; Cardinalli IA; Brandalise SR; de Paula Queiroz RG; Scrideli CA; Donson AM; Foreman NK; Tone LG; Valera ET
Cancer Gene Ther; 2023 Aug; 30(8):1105-1113. PubMed ID: 37041276
[TBL] [Abstract][Full Text] [Related]
18. Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome.
Jünger ST; Andreiuolo F; Mynarek M; Dörner E; Zur Mühlen A; Rutkowski S; von Bueren AO; Pietsch T
Childs Nerv Syst; 2020 Nov; 36(11):2693-2700. PubMed ID: 32474813
[TBL] [Abstract][Full Text] [Related]
19. Ependymomas of the spinal region in adults: Clinical and pathological features and MYCN expression levels in spinal ependymomas and myxopapillary ependymomas.
Topel G; Dirilenoğlu F; Sevin İE; Kahraman A
Ann Diagn Pathol; 2024 Jun; 70():152299. PubMed ID: 38555652
[TBL] [Abstract][Full Text] [Related]
20. L1CAM Is Not a Reliable Diagnostic Biomarker for Distinguishing Supratentorial Ependymomas, ZFTA Fusion-Positive From Other Central Nervous System Tumors.
Aboubakr O; Metais A; Berthaud C; Gigant P; Mehdi L; Pucelle N; Lacombe J; Hasty L; Chrétien F; Lechapt E; Varlet P; Tauziède-Espariat A
J Neuropathol Exp Neurol; 2022 Jan; 81(1):82-85. PubMed ID: 35062030
[No Abstract] [Full Text] [Related]
[Next] [New Search]
